Treatment Resistant Bipolar Disorder

Abstract

Many patients diagnosed with bipolar disorder respond incompletely or unsatisfactorily to available treatments. Defining refractoriness in bipolar disorder is a complex issue and should concern and include either every phase and pole or the disorder as a whole. There are only limited and sometimes confusing data on the treatment of refractory bipolar patients. The objective of this paper was to review the evidence for treatment options in treatment resistant patients on depressive, manic attack and maintanence phase as found in randomized controlled trials and with special attention to the definition and assessment of treatment resistance.

 

Keywords

• Bipolar disorder, treatment resistance

Tedaviye Dirençli Bipolar Bozukluk

Öz

Bipolar bozukluk tanısı alan pek çok hasta uygun tedavilere yetersiz yanıt verirler. Bipolar bozuklukta dirençliliği tanımlamak oldukça zordur ve hastalığın hem bütününü ve hem de her atağını ayrı ayrı kapsamalıdır. Tedaviye dirençli bipolar bozukluk hastaları ile ilgili çalışmalar az sayıdadır ve çelişkili bilgiler içermektedirler. Bu yazının amacı, mani, depresyon atağında olan ya da idame dönemdeki tedaviye dirençli bipolar hastaların randomize kontrollü çalışmalar düzeyinde verilerini değerlendirmek ve tedaviye direncin değerlendirilmesi ve tanımlanmasına dikkat çekmektir.

 

Anahtar Kelimeler

• Bipolar bozukluk, tedavi direnci

Kaynakça

1. Ahn YM, Nam JY, Culver JL, Marsh WK, Bonner JC, Ketter TA (2011) Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression. Ann Clin Psychiatry, 23:17–24.
2. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M (2006) Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord, 8:485–489.
3. Altshuler LL, Post RM, Hellemann G, Leverich GS, Nolen WA, Frye MA et al.(2009) Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry, 70:450–
4. Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR et al. (2011) Double-blind, randomized, placebo- controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord, 129:327–331.
5. Bailine S, Fink M, Knapp R, Petrides G, Husain MM, Rasmussen K et al. (2010) Electroconvulsive therapy ıs equally effective in unipolar and bipolar depression. Acta Psychiatr Scand, 121:431–436.
6. BALANCE investigators and collaborators, Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A et al. (2010) Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (balance): a randomised open- label trial. Lancet, 375:385–395.
7. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA et al. (1998) Consensus statement on panic disorder from the ınternational consensus group on depression and anxiety. J Clin Psychiatry, 59 (Suppl 8):47–54.
8. Baumgartner A (2000) Thyroxine and the treatment of affective disorders: an overview of the results of basic and clinical research. Int J Neuropsychopharmacol, 3:149–165.

9. Behzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M (2009) Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. Acta Psychiatr Scand, 120:441–445.
10. Benedetti A, Di Paolo A, Lastella M, Casamassima F, Candiracci C, Litta A et al. (2010) Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study. Clin Pract Epidemiol Ment Health, 6:30-35.
11. Benedetti F, Barbini B, Fulgosi MC, Colombo C, Dallaspezia S, Pontiggia A et al. (2005) combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. J Clin Psychiatry, 66:1535–1540.
12. Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hough DW (2011) Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord, 129:252–260.
13. Bowden CL (2004) Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry, 65 (Suppl 15):21– 24.
14. Bowden CL (2005) Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. Journal Clin Psychiatry, 66 (Suppl 3):12–19.
15. Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH, Degenhardt E et al. (2009) Olanzapine/fluoxetine Combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol, 12:773–782.
16. Burt T, Sachs GS, Demopulos C (1999) Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry, 45:959–964.
17. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY (1996) Clozapine for treatment- refractory mania. Am J Psychiatry, 153:759–764.
18. Chang JS, Ha KS, Young Lee K, Sik Kim Y, Min Ahn Y (2006) The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry, 67:461–467.
19. Chen J, Muzina DJ, Kemp DE, Conroy C, Chan P, Serrano MB et al. (2011) Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study. Hum Psychopharmacol, 26:588–595.
20. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D et al. (2003) Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry, 64:451–458.
21. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S et al. (2011) Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet, 378:1306–1315.
22. Dell'Osso B, Mundo E, D'Urso N, Pozzoli S, Buoli M, Ciabatti M et al. (2009) Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. Bipolar Disord, 11:76–81.
23. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM (1997) Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry, 58:470–478.
24. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S et al. (2010) A randomized add-on trial of an n- methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry, 67:793–802.
25. Evins AE, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs G (2006) A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord, 8:75–80.
26. Erfurth A, Michael N, Stadtland C, Arolt V (2002) Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology, 45 (Suppl 1):33–36.
27. Fountoulakis KN (2012) Refractoriness in bipolar disorder: definitions and evidence-based treatment. CNS Neurosci Ther, 18:227–
28. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW et al (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. remission, recovery, relapse, and recurrence. Arch Gen Psychiatry, 48:851– 855.
29. Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE Jr, Walden J et al. (2007) A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry, 164:1242–1249.
30. Garvey MJ, Hwang S, Teubner-Rhodes D, Zander J, Rhem C (1987) Dextroamphetamine treatment of mania. J Clin Psychiatry, 48:412–413.
31. Gitlin M (2006) Treatment-resistant bipolar disorder. Mol Psychiatry, 11:227–240.
32. Goldberg JF, Katherine EB, Carrie JE (2004) Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry, 161:564–566.
33. González-Isasi A, Echeburşa E, Mosquera F, Ibáñez B, Aizpuru F, González-Pinto A (2010) Long-term efficacy of a psychological ıntervention program for patients with refractory bipolar disorder: a pilot study. Psychiatry Res, 176:161–165.
34. Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC et al. (2003) Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology, 28:1374–1382.
35. Holtzheimer PE, Kelley ME, Gross RE, Filkowski MM, Garlow SJ, Barrocas A et al. (2012) Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry, 69:150–158.
36. Inoue T, Nakagawa S, Kitaichi Y, Izumi T, Tanaka T, Masui T et al. (2006) Long-term outcome of antidepressant-refractory depression: the relevance of unrecognized bipolarity. J Affect Disord, 95:61–67.
37. Janowsky DS, el-Yousef MK, Davis JM, Hubbard B, Sekerke HJ (1972) Cholinergic reversal of manic symptoms. Lancet, 1:1236– 1237.
38. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA et al. (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry, 59:530–537.
39. Juruena MF, Ottoni GL, Machado-Vieira R, Carneiro RM, Weingarthner N, Marquardt AR et al. (2009) Bipolar I and II disorder residual symptoms: Oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry, 33:94–99.
40. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A et al. (2003a) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry ,160:1651–1658.
41. Keck PE, Versiani M, Potkin S, West SA, Giller E, Ice K (2003b) Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry, 160:741–748.
42. Keck PE , Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM et al. (2006) A randomized, double-blind, placebo- controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry, 67:626–637.
43. Keck P, Sanchez R, Torbeyns A, Marcus R, McQuade R, Forbes A (2007) Aripiprazole monotherapy in the treatment of acute bipolar ı mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord, 112:36–49.
44. Keck PE Jr., McElroy SL (2001) Definition, evaluation, and management of treatment refractory mania. Psychopharmacol Bull, 35:130–148.
45. Kelly T, Lieberman DZ (2009) The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. J Affect Disord, 116:222–226.
46. Kemp DE, Gilmer WS, Fleck J, Straus JL, Dago PL, Karaffa M (2007) Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry, 31:574–577.
47. Ketter TA (2008) Combination therapy versus monotherapy in bipolar disorder. J Clin Psychiatry, 69:e34.
48. Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM (2006) Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry, 18:169–172.
49. Kora K (2014) Dirençli mani tedavisine yaklaşım. Türkiye Klinikleri J Psychiatry- Special Topics, 7(1):15-19.
50. Kordy H, Krämer B, Palmer RL, Papezova H, Pellet J, Richard M, Treasure J (2002) Remission, recovery, relapse, and recurrence in eating disorders: conceptualization and ıllustration of a validation strategy. J Clin Psychol, 58:833–846.
51. Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D, Serra G (2012) The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord, 136:163– 166.
52. Lasser RA, Baldessarini RJ (1997) Thyroid hormones in depressive disorders: a reappraisal of clinical utility. Harvard Rev Psychiatry, 4:291–305.
53. Levy NA, Janicak PG (2000) Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord, 2:108–119.
54. Lipsman N, McIntyre RS, Giacobbe P, Torres C, Kennedy SH, Lozano AM (2010) Neurosurgical treatment of bipolar depression: defining treatment resistance and ıdentifying surgical targets. Bipolar Disord, 12:691–701.
55. Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C et al. (2009) A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord, 11:827–839.
56. Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G et al. (2008) A double-blind, randomized, placebo- controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry, 69:1237–1245.
57. Malhi GS, Bargh DM, Cashman E, Frye MA, Gitlin M (2012) The clinical management of bipolar disorder complexity using a stratified model. Bipolar Disord, 14 (Suppl 2):66–89.
58. Menza M, Easton J, Flaum M, Frank D, Goldberg I, Michell M (1998) Approaches to the treatment of lithium-resistant mania. Psychiatr Med, 6:73–87.
59. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M et al. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry, 64:543–552.
60. Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Wisniewski SR, Kogan JN et al. (2007) Psychosocial treatments for bipolar depression: a 1-year randomized trial from the systematic treatment enhancement program. Arch Gen Psychiatry, 64:419– 426.
61. Mukherjee S, Sackeim HA, Lee C (1998) Unilateral ECT in the treatment of manic episodes. Convuls Ther, 4:74–80.
62. Müller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J (2000) Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. european valproate mania study group. J Clin Psychopharmacol, 20:195–203.
63. Nierenberg AA, DeCecco LM (2001) Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry, 62 (Suppl 16):5–9.
64. Nierenberg AA, Wright EC (1999) Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry, 60 (Suppl 22):7–11.
65. Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ et al. (2006) Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry, 163:210–216.
66. Oral TE(2014) Dirençli bipolar depresyon tedavisine yaklaşım. Türkiye Klinikleri J Psychiatry- Special Topics, 2(1):20-23.
67. Post RM, Altshuler LL, Frye MA, Suppes T, Rush AJ, Keck PE et al. (2001) Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord, 3:259–265.
68. Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW et al. (2006) Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry, 189:124–131.
69. Sachs GS (1996) Treatment-resistant bipolar depression. Psychiatr Clin North Am, 19:215–236.
70. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W et al. (2006) Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol, 20:536–546.
71. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L et al. (2007) Effectiveness of adjunctive antidepressant treatment for bipolar depression. New Engl J Med, 356:1711–1722.
72. Schaffer A, Levitt AJ (2005) Double-blind, placebo-controlled pilot study of mexiletine for acute mania or hypomania. J Clin Psychopharmacol, 25:507–508.
73. Schaffer A, Zuker P, Levitt A (2006) Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord, 96:95–99.
74. Sharma V, Khan M, Corpse C (2008) Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review. J Affect Disord, 111:100–105.
75. Sheehan DV (2001) Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. J Clin Psychiatry, 62 (Suppl 19):26–31.
76. Sienaert P, Vansteelandt K, Demyttenaere K, Peuskens J (2009) Ultra-brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of response. Bipolar Disord, 11:418–424.
77. Small JG, Klapper MH, Kellams JJ, Miller MJ, Milstein V,Sharpley PH et al. (1998) Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry, 45:727–732.
78. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D (2007) Acute bipolar mania: a systematic review and meta-analysis of co- therapy vs. monotherapy. Acta Psychiatr Scand ,115:12–20.
79. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ (1999) Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant ıllness and a history of mania. Am J Psychiatry, 156:1164–1169.
80. Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J (2012) Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol, 32:46–55.
81. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL et al. (2004) Relapse prevention in bipolar I disorder: 18- month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry, 184:337–345.
82. Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN et al. (2009) The international society for bipolar disorders (ISBD) task force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord, 11:453–473.
83. Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D (2011) Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med, 8:e1000434.
84. Van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ et al. (2009) Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry, 70:223–231.
85. Vieta E, T'joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R et al. (2008) Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry, 165:1316–1325.
86. Weisler R, Dunn J (2003) P.2.150 Ziprasidone in adjunctive treatment of acute bipolar mania: a randomized, double-blind placebo-controlled trial. Eur Neuropsychopharmacol, 13:S344–45.
87. Yatham LN (2004) Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry, 65 (Suppl 10):28–35.
88. Yatham LN (2005) Atypical antipsychotics for bipolar disorder. Psychiatr Clin North Am, 28:325–347.
89. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M et al. (2013) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) Collaborative Update of CANMAT guidelines for the management of patients with bipolar disorder: update (2013) Bipolar Disord, 15:1–44.
90. Yatham LN, Calabrese JR, Kusumakar V (2003) Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord, 5:85–97.
91. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B et al. (2010) A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry, 71:150–162.
92. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G (2010) Glutamatergic modulators: the future of treating mood disorders? Harvard Rev Psychiatry, 18:293–303.
93. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A et al. (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry, 71:939–946.
94. Zornberg GL, Pope HG (1993) Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacology, 13:397–408.